From the 56th Annual Scientific Session of the American College of Cardiology: ARISE: Succinobucol delivers mixed results in phase 3 trial of patients with ACS


Succinobuccol, an investigational monosuccinic acid ester of probucol, was not associated with a reduction in a composite end point of major cardiovascular events in patients diagnosed with acute coronary syndrome (ACS), but use of the agent did result in improvements on certain secondary end points.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.